Maintenance with rituximab is not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIB MAXIMA study

被引：0
|
作者：
Witzens-Harig, M. [1 ]
Di Rocco, A. [2 ]
van Hazel, G. [3 ]
Chamone, D. [4 ]
Ruffert, K.
Rowe, J. [5 ]
Arcaini, L. [6 ]
Poddubnaya, I. [7 ]
Ho, A. [1 ]
Ivanova, V. [8 ]
Vranowsky, A. [9 ]
Oertel, S. [10 ]
Thurley, D. [11 ]
Foa, R. [2 ]
机构：
[1] Univ Heidelberg, Heidelberg, Germany
[2] Sapienza Univ, Rome, Italy
[3] Mt Hosp, Perth, WA, Australia
[4] FMUSP, Hosp Clin, Sao Paulo, Brazil
[5] Technion Israel Inst Technol, Haifa, Israel
[6] Univ Pavia, I-27100 Pavia, Italy
[7] Blokhin Canc Res Ctr, Moscow, Russia
[8] Botkin Municipal Clin Hosp, Moscow, Russia
[9] Natl Oncol Inst, Bratislava, Slovakia
[10] F Hoffman La Roche Ltd, Basel, Switzerland
[11] Roche Prod Pty Ltd, Dee Why, Australia
来源：
ONKOLOGIE | 2012年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [1] Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study
    Mathias Witzens-Harig
    Robin Foá
    Alice Di Rocco
    Guy van Hazel
    Dalton F. A. Chamone
    Jacob M. Rowe
    Luca Arcaini
    Irina Poddubnaya
    Anthony D. Ho
    Valentina Ivanova
    Andrej Vranovsky
    Dan Thurley
    Stephan Oertel
    Annals of Hematology, 2014, 93 : 1717 - 1724
  • [2] Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study
    Witzens-Harig, Mathias
    Foa, Robin
    Di Rocco, Alice
    van Hazel, Guy
    Chamone, Dalton F. A.
    Rowe, Jacob M.
    Arcaini, Luca
    Poddubnaya, Irina
    Ho, Anthony D.
    Ivanova, Valentina
    Vranovsky, Andrej
    Thurley, Dan
    Oertel, Stephan
    ANNALS OF HEMATOLOGY, 2014, 93 (10) : 1717 - 1724
  • [3] Erratum to: Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study
    Mathias Witzens-Harig
    Robin Foá
    Alice Di Rocco
    Guy van Hazel
    Dalton F. A. Chamone
    Jacob M. Rowe
    Luca Arcaini
    Irina Poddubnaya
    Anthony D. Ho
    Valentina Ivanova
    Andrej Vranovsky
    Dan Thurley
    Stephan Oertel
    Annals of Hematology, 2014, 93 : 1807 - 1807
  • [4] Safety in patients receiving maintenance rituximab for follicular lymphoma: Results from the phase IIIb MAXIMA trial
    Wenger, M. K.
    Foa, R.
    Arcaini, L.
    Vranovsky, A.
    Ivanova, V.
    Van Hazel, G. A.
    Kurtovic, S.
    Duran, S.
    Gamba, E.
    Thurley, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Safety in Patients Receiving Maintenance Rituximab for Follicular Lymphoma: Results from Phase IIIb MAXIMA Trial
    Witzens-Harig, Mathias
    Hipp, Joachim
    Ho, Anthony D.
    Nikolov, Nikolai
    Thurley, Daniel
    Hensel, Manfred
    Oertel, Stefan
    Wenger, Michael
    BLOOD, 2008, 112 (11) : 697 - 697
  • [6] Safety in patients receiving maintenance rituximab (Mabthera®) in follicular lymphoma:: Results from the phase IIIB maxima trial
    Thurley, D.
    Arcaini, L.
    Foa, R.
    Vranovsky, A.
    Ivanova, V.
    Van Hazel, G.
    Kurtovic, S.
    Duran, S.
    Gamba, E.
    Wenger, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 210 - 210
  • [7] Safety and Efficacy in Patients Receiving Maintenance Rituximab for Follicular Lymphoma: Early Results From Phase IIIb MAXIMA Trial
    Witzens-Harig, Mathias
    van Hazel, Guy
    Chamone, Dalton F. A.
    Ruffert, Klaus
    Rowe, Jacob M.
    Lazzarino, Mario
    Foa, Robin
    Poddubnaya, Irina
    Ho, Anthony D.
    Ivanova, Valentina
    Vranowsky, Andrej
    Hipp, Joachim
    Oertel, Stefan
    BLOOD, 2009, 114 (22) : 1446 - 1446
  • [8] Early results from phase IIIb MAXIMA trial: Safety and efficacy in patients receiving maintenance Rituximab for follicular lymphoma
    Witzens-harig, M.
    Hipp, J.
    Ruffert, K.
    Becker, M.
    Hensel, M.
    Schwaner, I
    Fuxius, S.
    Gronschek, M.
    Pies, A.
    Schaefers, M.
    Schroeder, J.
    Ho, A.
    ONKOLOGIE, 2010, 33 : 159 - 159
  • [9] Maintenance Rituximab every 2 months for 2 years is effective and well tolerated in patients with follicular lymphoma with both standard or rapid infusion: Updated results from the phase IIIb MAXIMA study
    Foa, R.
    Di Rocco, A.
    van Hazel, G.
    Chamone, D. F.
    Ruffert, K.
    Rowe, J. M.
    Arcaini, L.
    Poddubnaya, I
    Ho, A. D.
    Ivanova, V
    Vranowsky, A.
    Witzens-Harig, M.
    ONKOLOGIE, 2011, 34 : 98 - 98
  • [10] Maintenance Rituximab Every 2 Months for 2 Years Is Effective and Well Tolerated In Patients with Follicular Lymphoma with Both Standard or Rapid Infusion: Updated Results From the Phase IIIb MAXIMA Study
    Foa, Robin
    Di Rocco, Alice
    van Hazel, Guy
    Chamone, Dalton Fa
    Ruffert, Klaus
    Rowe, Jacob M.
    Arcaini, Luca
    Poddubnaya, Irina
    Ho, Anthony D.
    Ivanova, Valentina
    Vranovsky, Andrej
    Witzens-Harig, Mathias
    BLOOD, 2010, 116 (21) : 1608 - 1609
12345